Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMP Prima BioMed	$1.70 -4.0%	$1.69	$1.32 ▼ $2.72	$248.80M	1.66	158,282 shs	84,613 shs
IRD Opus Genetics	$1.16 +0.4%	$1.08	$0.65 ▼ $1.75	$69.19M	0.01	536,368 shs	79,028 shs
MREO Mereo BioPharma Group	$1.78 +4.4%	$2.09	$1.47 ▼ $4.95	$282.23M	0.47	1.74 million shs	1.60 million shs
PBYI Puma Biotechnology	$5.04 -4.1%	$3.74	$2.22 ▼ $6.07	$253.87M	1.3	480,176 shs	433,349 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMP Prima BioMed	0.00%	+2.31%	+2.91%	-8.76%	-27.16%
IRD Opus Genetics	0.00%	-4.17%	-2.54%	+12.75%	+114,999,900.00%
MREO Mereo BioPharma Group	0.00%	-2.30%	-3.41%	-24.11%	-64.80%
PBYI Puma Biotechnology	0.00%	-8.38%	+60.06%	+62.54%	+106.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMMP Prima BioMed	0.9771 of 5 stars	3.5	1.0	0.6	0.0	0.0
IRD Opus Genetics	1.6506 of 5 stars	3.5	0.0	1.9	0.0	0.6
MREO Mereo BioPharma Group	1.9085 of 5 stars	3.6	1.0	2.6	1.7	0.0
PBYI Puma Biotechnology	3.8922 of 5 stars	3.5	1.0	1.8	4.2	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMP Prima BioMed	3.00	Buy	$7.00	312.01% Upside
IRD Opus Genetics	3.00	Buy	$7.33	534.92% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.40	316.90% Upside
PBYI Puma Biotechnology	3.00	Buy	$7.00	39.03% Upside

Current Analyst Ratings Breakdown

Latest IRD, PBYI, IMMP, and MREO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.00 ➝ $8.00
7/10/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
6/27/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMP Prima BioMed	N/A	N/A	N/A	N/A	$1.05 per share	N/A
IRD Opus Genetics	$15.42M	4.49	N/A	N/A	$0.21 per share	5.50
MREO Mereo BioPharma Group	$10M	28.22	N/A	N/A	$0.39 per share	4.55
PBYI Puma Biotechnology	$238.06M	1.07	$0.82 per share	6.16	$1.88 per share	2.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
IRD Opus Genetics	-$57.53M	-$1.92	N/A	N/A	N/A	-377.89%	-384.33%	-148.90%	11/11/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-80.00%	-66.94%	11/11/2025 (Estimated)
PBYI Puma Biotechnology	$30.28M	$0.98	5.14	13.25	N/A	20.38%	53.15%	23.51%	11/6/2025 (Estimated)

Latest IRD, PBYI, IMMP, and MREO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	IRD Opus Genetics	-$0.25	-$0.12	+$0.13	-$0.12	$4.27 million	$2.88 million
8/12/2025	Q2 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$7.80 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMP Prima BioMed	N/A	18.86	N/A
IRD Opus Genetics	0.06	1.90	1.90
MREO Mereo BioPharma Group	N/A	8.13	8.13
PBYI Puma Biotechnology	0.10	1.73	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMP Prima BioMed	2.32%
IRD Opus Genetics	14.97%
MREO Mereo BioPharma Group	62.83%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
IMMP Prima BioMed	3.07%
IRD Opus Genetics	6.60%
MREO Mereo BioPharma Group	5.50%
PBYI Puma Biotechnology	23.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMP Prima BioMed	2,021	146.79 million	142.28 million	Optionable
IRD Opus Genetics	14	59.91 million	55.95 million	N/A
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
PBYI Puma Biotechnology	200	50.37 million	38.64 million	Optionable

IRD, PBYI, IMMP, and MREO Headlines

Recent News About These Companies

Puma Biotechnology (NASDAQ:PBYI) Upgraded to Buy at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Upgraded by Wall Street Zen to Buy Rating

August 18, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

August 16, 2025 | marketbeat.com

Additional Considerations Required While Assessing Puma Biotechnology's (NASDAQ:PBYI) Strong Earnings

August 15, 2025 | finance.yahoo.com

Puma Biotechnology Reports Strong Q2 2025 Earnings

August 13, 2025 | msn.com

Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT

August 12, 2025 | msn.com

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

August 12, 2025 | zacks.com

Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?

August 12, 2025 | zacks.com

Results: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

August 10, 2025 | finance.yahoo.com

Puma Biotechnology (NASDAQ:PBYI) Downgraded to Hold Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Mackenzie Financial Corp Acquires 79,060 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

August 9, 2025 | marketbeat.com

PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

August 8, 2025 | zacks.com

Puma (PBYI) Q2 Revenue Rises 11%

August 8, 2025 | fool.com

Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Puma Biotechnology (NASDAQ:PBYI) shareholders have endured a 70% loss from investing in the stock five years ago

August 2, 2025 | finance.yahoo.com

Puma Biotechnology (PBYI) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200-Day Moving Average - Here's What Happened

July 30, 2025 | marketbeat.com

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

July 24, 2025 | businesswire.com

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $90,990.00 in Stock

July 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD, PBYI, IMMP, and MREO Company Descriptions

Prima BioMed NASDAQ:IMMP

$1.70 -0.07 (-4.01%)

As of 03:47 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Opus Genetics NASDAQ:IRD

$1.16 +0.01 (+0.43%)

As of 03:45 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Mereo BioPharma Group NASDAQ:MREO

$1.78 +0.08 (+4.41%)

As of 03:47 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Puma Biotechnology NASDAQ:PBYI

$5.04 -0.22 (-4.10%)

As of 03:46 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time